株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) :パイプライン製品の分析

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 255954
出版日 ページ情報 英文 218 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) :パイプライン製品の分析 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 218 Pages
概要

ロストリジウム・ディフィシルは消化管が感染するグラム陽性芽胞形成菌系の微生物です。入院患者や要介護者 (在宅/施設とも) などがしばしば、この微生物の毒素に感染し、消化器系疾患を引き起こしています。この疾患の症状には、下痢、大腸炎、中毒性巨大結腸、敗血症などが含まれていますが、これらは一括して「クロストリジウム・ディフィシル関連疾患」(CDAD)と呼ばれています。

当レポートでは、世界各国でのクロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):企業で開発中の治療薬

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):大学/機関で研究中の治療薬

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):企業で開発中の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):大学/機関で研究中の製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患) の治療薬開発に従事している企業

  • Absynth Biologics Limited
  • Actelion Ltd
  • Adenium Biotech ApS
  • AIMM Therapeutics B.V.
  • AmpliPhi Biosciences Corporation
  • Angothera GmbH
  • Appili Therapeutics
  • Assembly Biosciences, Inc.
  • AvidBiotics Corp.
  • C3 Jian, Inc
  • Da Volterra
  • 第一三共
  • e-Therapeutics Plc
  • Evec, Inc.
  • GangaGen Inc.
  • ImmunoBiology Limited
  • Immuron Limited
  • Inovio Pharmaceuticals, Inc.
  • Integrated BioTherapeutics, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MGB Biopharma Limited
  • Microbiotix, Inc.
  • Micropharm Limited
  • Morphochem AG
  • Nanotherapeutics, Inc.
  • Novabiotics Limited
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • 大塚ホールディングス
  • Pfizer Inc.
  • Procarta Biosystems Limited
  • Prokarium Limited
  • Rebiotix Inc.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Shire Plc
  • Sorrento Therapeutics, Inc.
  • Stellar Biotechnologies, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valevia UK Limited
  • Valneva SE
  • VaxInnate Corporation

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):最近のパイプライン動向

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):休止中のプロジェクト

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):開発が中止された製品

クロストリジウム・ディフィシル感染症 (クロストリジウム・ディフィシル関連疾患):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8583IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 11, 7, 32, 13 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 7 molecules, respectively for Clostridium difficile Infections.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview
  • Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
  • Drug Profiles
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Antibiotx ApS, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corporation, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by e-Therapeutics Plc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Morphochem AG, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Procarta Biosystems Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Venenum Biodesign, L.L.C, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..1), H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..2), H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top